CASI Pharmaceuticals Inc

CASI

0.207USD

0.0000.00%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

CASI Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

96 / 158

Overall Ranking

234 / 4494

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

CASI Pharmaceuticals Inc Highlights

StrengthsRisks

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.

Growing

The company is in a growing phase, with the latest annual income totaling USD 28.54M.

Overvalued

The company’s latest PE is -0.07, at a high 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 43.10K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 12.46.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

4.000

Target Price

+1827.71%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Its latest quarterly revenue reached 3.08M, representing a year-over-year decrease of 60.54%, while its net profit experienced a year-over-year decrease of 29.64%.

Score

Industry at a Glance

Previous score

7.18

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.30

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.54

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.05

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of CASI Pharmaceuticals Inc is 8.80, ranking 7 out of 158 in the Pharmaceuticals industry. Its current P/E ratio is -0.07, which is 0.00% below the recent high of -0.07 and -5570.70% above the recent low of -3.89.

Score

Industry at a Glance

Previous score

8.80

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 96/158

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of CASI Pharmaceuticals Inc is 8.00, ranking 57 out of 158 in the Pharmaceuticals industry. The average price target is 4.00, with a high of 4.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of CASI Pharmaceuticals Inc is 6.26, ranking 131 out of 158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 0.77 and the support level at -0.07, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.01

Change

0.25

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-25

The latest institutional shareholding proportion is 15.33%, representing a quarter-over-quarter decrease of 1.03%. The largest institutional shareholder is James Simons, holding a total of 43.10K shares, representing 0.21% of shares outstanding, with 16.49% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Panacea Venture

4.53M

+27.60%

He (Wei-Wu)

3.75M

+6.54%

Chen (Zhenfeng)

2.26M

--

Sparkle Byte Ltd

1.02M

--

VR Adviser, LLC

987.26K

--

IDG Capital Partners

915.85K

+7.26%

Wealth Strategy Holding Ltd

908.79K

--

Woodline Partners LP

165.64K

--

Renaissance Technologies LLC

Star Investors

43.90K

+11.99%

Two Sigma Investments, LP

33.27K

+186.81%



1

2



CASI Pharmaceuticals Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

CASI Pharmaceuticals Inc

CASI

6.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.81 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Innoviva Inc

INVA

8.56 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

8.40 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Catalyst Pharmaceuticals Inc

CPRX

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Jazz Pharmaceuticals PLC

JAZZ

8.35 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment